Last reviewed · How we verify

Camrelizumab and Apatinib

Chinese Academy of Medical Sciences · Phase 3 active Small molecule

Camrelizumab and Apatinib is a PD-1 inhibitor + VEGFR2 tyrosine kinase inhibitor combination Small molecule drug developed by Chinese Academy of Medical Sciences. It is currently in Phase 3 development for Hepatocellular carcinoma, Gastric cancer, Non-small cell lung cancer. Also known as: Targeted therapy, cryoablation.

Camrelizumab blocks PD-1 to enhance immune response while apatinib inhibits VEGFR2 to suppress tumor angiogenesis, combining immunotherapy with anti-angiogenic effects.

Camrelizumab blocks PD-1 to enhance immune response while apatinib inhibits VEGFR2 to suppress tumor angiogenesis, combining immunotherapy with anti-angiogenic effects. Used for Hepatocellular carcinoma, Gastric cancer, Non-small cell lung cancer.

At a glance

Generic nameCamrelizumab and Apatinib
Also known asTargeted therapy, cryoablation
SponsorChinese Academy of Medical Sciences
Drug classPD-1 inhibitor + VEGFR2 tyrosine kinase inhibitor combination
TargetPD-1 (camrelizumab); VEGFR2 (apatinib)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Camrelizumab is a PD-1 inhibitor that releases the brakes on T-cell mediated anti-tumor immunity by blocking the PD-1/PD-L1 checkpoint. Apatinib is a tyrosine kinase inhibitor targeting VEGFR2 that reduces tumor blood vessel formation and has immunomodulatory effects. Together, they synergize to enhance anti-tumor immunity while limiting tumor vascularization.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Camrelizumab and Apatinib

What is Camrelizumab and Apatinib?

Camrelizumab and Apatinib is a PD-1 inhibitor + VEGFR2 tyrosine kinase inhibitor combination drug developed by Chinese Academy of Medical Sciences, indicated for Hepatocellular carcinoma, Gastric cancer, Non-small cell lung cancer.

How does Camrelizumab and Apatinib work?

Camrelizumab blocks PD-1 to enhance immune response while apatinib inhibits VEGFR2 to suppress tumor angiogenesis, combining immunotherapy with anti-angiogenic effects.

What is Camrelizumab and Apatinib used for?

Camrelizumab and Apatinib is indicated for Hepatocellular carcinoma, Gastric cancer, Non-small cell lung cancer.

Who makes Camrelizumab and Apatinib?

Camrelizumab and Apatinib is developed by Chinese Academy of Medical Sciences (see full Chinese Academy of Medical Sciences pipeline at /company/chinese-academy-of-medical-sciences).

Is Camrelizumab and Apatinib also known as anything else?

Camrelizumab and Apatinib is also known as Targeted therapy, cryoablation.

What drug class is Camrelizumab and Apatinib in?

Camrelizumab and Apatinib belongs to the PD-1 inhibitor + VEGFR2 tyrosine kinase inhibitor combination class. See all PD-1 inhibitor + VEGFR2 tyrosine kinase inhibitor combination drugs at /class/pd-1-inhibitor-vegfr2-tyrosine-kinase-inhibitor-combination.

What development phase is Camrelizumab and Apatinib in?

Camrelizumab and Apatinib is in Phase 3.

What are the side effects of Camrelizumab and Apatinib?

Common side effects of Camrelizumab and Apatinib include Fatigue, Hypertension, Diarrhea, Immune-related adverse events (pneumonitis, hepatitis), Proteinuria.

What does Camrelizumab and Apatinib target?

Camrelizumab and Apatinib targets PD-1 (camrelizumab); VEGFR2 (apatinib) and is a PD-1 inhibitor + VEGFR2 tyrosine kinase inhibitor combination.

Related